Use of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine and its physiologically acceptable salts
    1.
    发明授权
    Use of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine and its physiologically acceptable salts 有权
    1- [4-(5-氰基吲哚-3-基)丁基] -4-(2-氨基甲酰基 - 苯并呋喃-5-基) - 哌嗪及其生理上可接受的盐

    公开(公告)号:US07642261B2

    公开(公告)日:2010-01-05

    申请号:US11946149

    申请日:2007-11-28

    IPC分类号: A61K31/497

    摘要: 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine or a physiologically acceptable salt thereof is used for the manufacture of a medicament for the treatment of sub-type anxiety disorders chosen from the sub-types panic disorder with or without agoraphobia, agoraphobia obsessive-compulsive spectrum disorders, social phobia, posttraumatic stress disorder, acute stress indication or generalized-anxiety disorder, bipolar disorders, mania, dementia substance-related disorders, sexual dysfunctions, eating disorders, obesity, anorexia and fibromyalgia. A preferred salt is 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine hydrochloride.

    摘要翻译: 1- [4-(5-氰基吲哚-3-基)丁基] -4-(2-氨基甲酰基 - 苯并呋喃-5-基) - 哌嗪或其生理学上可接受的盐用于制备用于治疗 亚型类焦虑障碍选自亚急性恐惧症,有或没有广场恐怖症,广场恐惧症强迫症频谱障碍,社会恐惧症,创伤后应激障碍,急性应激指征或全身焦虑症,双相性精神障碍,躁狂症,痴呆症相关 疾病,性功能障碍,饮食失调,肥胖,厌食和纤维肌痛。 优选的盐是1- [4-(5-氰基吲哚-3-基)丁基] -4-(2-氨基甲酰基 - 苯并呋喃-5-基) - 哌嗪盐酸盐。

    Use combined 5-HT1A agonists and selective serotonin reuptake inhibitors
    2.
    发明授权
    Use combined 5-HT1A agonists and selective serotonin reuptake inhibitors 有权
    使用组合的5-HT1A激动剂和选择性5-羟色胺再摄取抑制剂

    公开(公告)号:US07479492B2

    公开(公告)日:2009-01-20

    申请号:US10432047

    申请日:2001-11-02

    IPC分类号: A61K31/50 A61K31/4965

    CPC分类号: A61K31/496 A61K31/00

    摘要: The present invention relates to the use of compounds being combined selective serotonin (5-HT) reuptake inhibitors (SSRIs) and 5-HT1A receptor agonists, in particular of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine or a physiologically acceptable salt thereof or 3-{4-[4-(4-cyano-phenyl)-piperazin-1-yl]-butyl}-1H-indole-5-carbonitrile or a physiologically acceptable salt thereof, for the manufacture of a medicament for the treatment of chronic pain disorders or in treating other conditions where there is hyper-sensitization to painful signals, hyperalgesia, allodynia, enhanced pain perception, and enhanced memory of pain, as well as for the treatment of irritable bowel syndrome (IBS).

    摘要翻译: 本发明涉及化合物是组合的选择性5-羟色胺(5-HT)再摄取抑制剂(SSRI)和5-HT 1A受体激动剂,特别是1- [4-(5-氰基吲哚-3-基)丁基] - 4-(2-氨基甲酰基 - 苯并呋喃-5-基) - 哌嗪或其生理学上可接受的盐或3- {4- [4-(4-氰基 - 苯基) - 哌嗪-1-基] - 丁基} 吲哚-5-腈或其生理上可接受的盐,用于制备用于治疗慢性疼痛障碍或治疗其它对疼痛信号过敏的其他病症,痛觉过敏,异常性疼痛,增强的疼痛感知和增强的药物 记忆疼痛,以及治疗肠易激综合征(IBS)。

    Use of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine and its physiologically acceptable salts
    4.
    发明授权
    Use of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine and its physiologically acceptable salts 有权
    1- [4-(5-氰基吲哚-3-基)丁基] -4-(2-氨基甲酰基 - 苯并呋喃-5-基) - 哌嗪及其生理上可接受的盐

    公开(公告)号:US07371756B2

    公开(公告)日:2008-05-13

    申请号:US10994226

    申请日:2004-11-23

    IPC分类号: A61K31/497

    摘要: 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine or a physiologically acceptable salt thereof, for the treatment of sub-type anxiety disorders chosen from the sub-types: panic disorder with or without agoraphobia, agoraphobia, obsessive-compulsive spectrum disorders, social phobia, posttraumatic stress disorder, acute stress indication or generalized anxiety disorder, bipolar disorders, mania, dementia, substance-related disorders, sexual dysfunctions, eating disorders, obesity, anorexia, and fibromyalgia. A preferred salt is 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine hydrochloride.

    摘要翻译: 1- [4-(5-氰基吲哚-3-基)丁基] -4-(2-氨基甲酰基 - 苯并呋喃-5-基) - 哌嗪或其生理上可接受的盐,用于治疗选自以下的亚型焦虑症 子类型:伴有或不伴有恐惧症的恐慌症,广场恐惧症,强迫症频谱障碍,社交恐惧症,创伤后应激障碍,急性应激指征或广泛性焦虑症,双相情感障碍,躁狂症,痴呆,物质相关疾病,性功能障碍, 饮食失调,肥胖,厌食和纤维肌痛。 优选的盐是1- [4-(5-氰基吲哚-3-基)丁基] -4-(2-氨基甲酰基 - 苯并呋喃-5-基) - 哌嗪盐酸盐。

    NOVEL USE OF 1-[4-(5-CYANOINDOL-3-YL)BUTYL]-4-(2-CARBAMOYL-BENZOFURAN-5-YL)-PIPERAZINE AND ITS PHYSIOLOGICALLY ACCEPTABLE SALTS
    5.
    发明申请
    NOVEL USE OF 1-[4-(5-CYANOINDOL-3-YL)BUTYL]-4-(2-CARBAMOYL-BENZOFURAN-5-YL)-PIPERAZINE AND ITS PHYSIOLOGICALLY ACCEPTABLE SALTS 审中-公开
    1- [4-(5-氰基吲哚-3-基)丁基] -4-(2-羧甲基苯并呋喃-5-基) - 哌嗪及其生物学上可接受的盐的新用途

    公开(公告)号:US20120077825A1

    公开(公告)日:2012-03-29

    申请号:US13116680

    申请日:2011-05-26

    IPC分类号: A61K31/497 A61P25/22

    CPC分类号: A61K31/497

    摘要: 1-[4-(5-cyanoindo1-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine or a physiologically acceptable salt thereof is used for the manufacture of a medicament for the treatment of sub-type anxiety disorders chosen from the sub-types panic disorder with or without agoraphobia, agoraphobia. obsessive-compulsive spectrum disorders, social phobia, posttraumatic stress disorder, acute stress indication or generalized-anxiety disorder, bipolar disorders, mania, dementia, substance-related disorders, sexual dysfunctions, eating disorders, obesity, anorexia and fibromyalgia. A preferred salt is 1-[4-(5-cyanoindo1-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine hydrochloride.

    摘要翻译: 1- [4-(5-氰基吲哚-3-基)丁基] -4-(2-氨基甲酰基 - 苯并呋喃-5-基) - 哌嗪或其生理上可接受的盐用于制备用于治疗 亚型类焦虑障碍选自亚急性恐惧症,有或没有广场恐怖症,广场恐怖症。 强迫症频谱障碍,社交恐惧症,创伤后应激障碍,急性应激指征或广泛性焦虑症,双相性精神障碍,躁狂症,痴呆,物质相关疾病,性功能障碍,进食障碍,肥胖症,厌食症和纤维肌痛。 优选的盐是1- [4-(5-氰基吲哚-3-基)丁基] -4-(2-氨基甲酰基 - 苯并呋喃-5-基) - 哌嗪盐酸盐。

    NOVEL USE OF 1-[4-(5-CYANOINDOL-3-YL)BUTYL]-4-(2-CARBAMOYL-BENZOFURAN-5-YL)-PIPERAZINE AND ITS PHYSIOLOGICALLY ACCEPTABLE SALTS
    7.
    发明申请
    NOVEL USE OF 1-[4-(5-CYANOINDOL-3-YL)BUTYL]-4-(2-CARBAMOYL-BENZOFURAN-5-YL)-PIPERAZINE AND ITS PHYSIOLOGICALLY ACCEPTABLE SALTS 审中-公开
    1- [4-(5-氰基吲哚-3-基)丁基] -4-(2-羧甲基苯并呋喃-5-基) - 哌嗪及其生物学上可接受的盐的新用途

    公开(公告)号:US20100063062A1

    公开(公告)日:2010-03-11

    申请号:US12620049

    申请日:2009-11-17

    摘要: 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine or a physiologically acceptable salt thereof is used for the manufacture of a medicament for the treatment of sub-type anxiety disorders chosen from the sub-types panic disorder with or without agoraphobia, agoraphobia. obsessive-compulsive spectrum disorders, social phobia, posttraumatic stress disorder, acute stress indication or generalized-anxiety disorder, bipolar disorders, mania, dementia, substance-related disorders, sexual dysfunctions, eating disorders, obesity, anorexia and fibromyalgia. A preferred salt is 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine hydrochloride.

    摘要翻译: 1- [4-(5-氰基吲哚-3-基)丁基] -4-(2-氨基甲酰基 - 苯并呋喃-5-基) - 哌嗪或其生理学上可接受的盐用于制备用于治疗 亚型类焦虑障碍选自亚急性恐惧症,有或没有广场恐怖症,广场恐怖症。 强迫症频谱障碍,社交恐惧症,创伤后应激障碍,急性应激指征或广泛性焦虑症,双相性精神障碍,躁狂症,痴呆,物质相关疾病,性功能障碍,进食障碍,肥胖症,厌食症和纤维肌痛。 优选的盐是1- [4-(5-氰基吲哚-3-基)丁基] -4-(2-氨基甲酰基 - 苯并呋喃-5-基) - 哌嗪盐酸盐。